Bicycle Therapeutics plc (NASDAQ:BCYC) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Bicycle Therapeutics plc (NASDAQ:BCYC) have received a consensus recommendation of “Moderate Buy” from the nine research firms that are covering the firm, MarketBeat.com reports. Two investment analysts have rated the stock with a hold rating and seven have issued a buy rating on the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $38.75.

BCYC has been the subject of several recent research reports. Stephens initiated coverage on Bicycle Therapeutics in a research note on Friday, November 8th. They issued an “equal weight” rating and a $25.00 price objective for the company. HC Wainwright restated a “buy” rating and issued a $55.00 target price on shares of Bicycle Therapeutics in a report on Friday, November 1st. Royal Bank of Canada restated an “outperform” rating and issued a $35.00 target price on shares of Bicycle Therapeutics in a report on Friday, November 1st. B. Riley dropped their target price on Bicycle Therapeutics from $28.00 to $17.00 and set a “neutral” rating for the company in a report on Friday. Finally, Needham & Company LLC restated a “buy” rating and issued a $38.00 target price on shares of Bicycle Therapeutics in a report on Thursday, October 31st.

Bicycle Therapeutics Stock Performance

NASDAQ BCYC opened at $13.81 on Monday. The business has a fifty day moving average price of $22.78 and a 200 day moving average price of $22.76. Bicycle Therapeutics has a one year low of $12.17 and a one year high of $28.67. The company has a market cap of $953.58 million, a P/E ratio of -4.20 and a beta of 0.86.

Bicycle Therapeutics (NASDAQ:BCYC) last posted its quarterly earnings data on Thursday, October 31st. The company reported ($0.74) EPS for the quarter, beating the consensus estimate of ($0.78) by $0.04. Bicycle Therapeutics had a negative return on equity of 27.35% and a negative net margin of 450.64%. The firm had revenue of $2.68 million during the quarter, compared to the consensus estimate of $6.82 million. During the same period in the prior year, the company earned ($1.26) EPS. The firm’s revenue was down 50.0% compared to the same quarter last year. As a group, sell-side analysts predict that Bicycle Therapeutics will post -3.05 EPS for the current fiscal year.

Insider Transactions at Bicycle Therapeutics

In related news, CEO Kevin Lee sold 3,212 shares of the firm’s stock in a transaction dated Thursday, October 3rd. The stock was sold at an average price of $22.26, for a total transaction of $71,499.12. Following the completion of the transaction, the chief executive officer now directly owns 380,864 shares in the company, valued at $8,478,032.64. This trade represents a 0.84 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CAO Travis Alvin Thompson sold 6,256 shares of the firm’s stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $25.11, for a total value of $157,088.16. Following the transaction, the chief accounting officer now owns 19,241 shares of the company’s stock, valued at $483,141.51. This trade represents a 24.54 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 10,840 shares of company stock worth $259,128. 8.50% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Bicycle Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. GAMMA Investing LLC raised its position in Bicycle Therapeutics by 105.1% in the 3rd quarter. GAMMA Investing LLC now owns 2,026 shares of the company’s stock valued at $46,000 after purchasing an additional 1,038 shares in the last quarter. L & S Advisors Inc raised its position in Bicycle Therapeutics by 2.4% in the 3rd quarter. L & S Advisors Inc now owns 59,735 shares of the company’s stock valued at $1,352,000 after purchasing an additional 1,400 shares in the last quarter. Assetmark Inc. acquired a new stake in Bicycle Therapeutics in the 3rd quarter valued at about $34,000. China Universal Asset Management Co. Ltd. raised its position in Bicycle Therapeutics by 69.1% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 7,138 shares of the company’s stock valued at $162,000 after purchasing an additional 2,918 shares in the last quarter. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. raised its position in Bicycle Therapeutics by 0.6% in the 2nd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 888,081 shares of the company’s stock valued at $17,975,000 after purchasing an additional 4,976 shares in the last quarter. 86.15% of the stock is currently owned by hedge funds and other institutional investors.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.